Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: A randomised controlled trial

European Journal of Endocrinology

Volumn 175, Issue 4, 2016, Pages 345-352

  Van Raalte, Daniel H ^a   Bunck, Mathijs C ^a,b   Smits, Mark M ^a   Hoekstra, T ^a,c   Corner, Anja ^d   Diamant, Michaela ^a   Eliasson, Bjorn ^e   Taskinen, Marja Riitta ^d   Heine, Robert J ^a,b   Smith, Ulf ^e   Yki Järvinen, Hannele ^d   Mari, Andrea ^f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY OF HELSINKI   (Finland)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; EXENDIN 4; GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; PEPTIDE; VENOM;

ADULT; ARTICLE; CELL FUNCTION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MEAL; MIDDLE AGED; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTPRANDIAL STATE; TREATMENT OUTCOME;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PEPTIDES; POSTPRANDIAL PERIOD; TREATMENT OUTCOME; VENOMS;

EID: 84990068206     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-16-0286     Document Type: Article

References (23)

1. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009 58 773-795. (doi:10.2337/db09-9028)
2. Heine RJ, Diamant M, Mbanya JC & Nathan DM. Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure? BMJ 2006 333 1200-1204. (doi:10.1136/bmj.39022.462546.80)
3. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Yu D, Heise MA, Aftring RP et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. New England Journal of Medicine 2006 355 2427-2443. (doi:10.1056/NEJMoa066224)
4. U. K.prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U. K. Prospective Diabetes Study Group. Diabetes 1995 44 1249-1258. (doi:10.2337/diabetes.44.11.1249)
5. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009 32 762-768. (doi:10.2337/dc08-1797)
6. Smits MM, Bunck MC, Diamant M, Corner A, Eliasson B, Heine RJ, Smith U, Yki-Jarvinen H & van Raalte DH. Effect of 3 years of treatment with exenatide on postprandial glucagon levels. Diabetes Care 2016 39 e42-e43. (doi:10.2337/dc15-2489)
7. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocrine Reviews 2007 28 187-218. (doi:10.1210/10.1210/er.2006-0038)
8. Bunck MC, Corner A, Eliasson B, Heine RJ, Shaginian RM, Taskinen MR, Smith U, Yki-Jarvinen H & Diamant M. Effects of exenatide on measures of beta-cell function after 3 years in metformin-treated patients with type 2 diabetes. Diabetes Care 2011 34 2041-2047. (doi:10.2337/dc11-0291)
9. Retnakaran R, Kramer CK, Choi H, Swaminathan B & Zinman B. Liraglutide and the preservation of pancreatic beta-cell function in early type 2 diabetes: the LIBRA trial. Diabetes Care 2014 37 3270-3278. (doi:10.2337/dc14-0893)
10. Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG & Wintle ME. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clinical Therapeutics 2007 29 139-153. (doi:10.1016/j. clinthera.2007.01.015)
11. Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME & Maggs DG. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Current Medical Research and Opinion 2008 24 275-286. (doi:10.1185/030079908X253870)
12. Cervera A, Wajcberg E, Sriwijitkamol A, Fernandez M, Zuo P, Triplitt C, Musi N, DeFronzo RA & Cersosimo E. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. American Journal of Physiology Endocrinology and Metabolism 2008 294 E846-E852. (doi:10.1152/ajpendo.00030.2008)
13. Yki-Jarvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, Lahdenpera S, Nijpels G & Vahatalo M. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care 2007 30 1364-1369. (doi:10.2337/dc06-1357)
14. Mari A, Pacini G, Murphy E, Ludvik B & Nolan JJ. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care 2001 24 539-548. (doi:10.2337/diacare.24.3.539)
15. Mari A, Tura A, Gastaldelli A & Ferrannini E. Assessing insulin secretion by modeling in multiple-meal tests: role of potentiation. Diabetes 2002 51 (Supplement 1) S221-S226. (doi:10.2337/diabetes.51.2007.s221)
16. Mari A, Schmitz O, Gastaldelli A, Oestergaard T, Nyholm B & Ferrannini E. Meal and oral glucose tests for assessment of beta-cell function: modeling analysis in normal subjects. American Journal of Physiology Endocrinology and Metabolism 2002 283 E1159-E1166. (doi:10.1152/ajpendo.00093.2002)
17. Mari A & Ferrannini E. ß-cell function assessment from modelling of oral tests: an effective approach. Diabetes, Obesity & Metabolism 2008 10 (Supplement 4) 77-87. (doi:10.1111/j.1463-1326.2008.00946.x)
18. Mari A, Degn K, Brock B, Rungby J, Ferrannini E & Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007 30 2032-2033. (doi:10.2337/dc07-0310)
19. Mari A, Nielsen LL, Nanayakkara N, DeFronzo RA, Ferrannini E & Halseth A. Mathematical modeling shows exenatide improved betacell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Hormone and Metabolic Research 2006 38 838-844. (doi:10.1055/s-2006-956505)
20. Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, Krarup T, Schmitz O, Zdravkovic M, Le-Thi T et al. Liraglutide, a oncedaily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabetic Medicine 2008 25 152-156. (doi:10.1111/j.1464-5491.2007.02333.x)
21. Foley JE, Bunck MC, Moller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ & Diamant M. Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. Diabetologia 2011 54 1985-1991. (doi:10.1007/s00125-011-2167-8)
22. Linnebjerg H, Park S, Kothare PA, Trautmann ME, Mace K, Fineman M, Wilding I, Nauck M & Horowitz M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regulatory Peptides 2008 151 123-129. (doi:10.1016/j. regpep. 2008.07.003)
23. Meier JJ, Rosenstock J, Hincelin-Mery A, Roy-Duval C, Delfolie A, Coester HV, Menge BA, Forst T & Kapitza C. Contrasting effects of lixisenatide and liraglutide on postprandial glycemic control, gastric emptying, and safety parameters in patients with type 2 diabetes on optimized insulin glargine with or without metformin: a randomized, open-label trial. Diabetes Care 2015 38 1263-1273. (doi:10.2337/dc14-1984)